<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883138</url>
  </required_header>
  <id_info>
    <org_study_id>GG-GIGA-2050-001</org_study_id>
    <nct_id>NCT04883138</nct_id>
  </id_info>
  <brief_title>Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients</brief_title>
  <official_title>A Phase 1 Single Ascending Dose Study of a Recombinant Hyperimmune Polyclonal Antibody Against SARS CoV-2 (GIGA-2050) in Patients Hospitalized With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GigaGen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GigaGen, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of single ascending IV&#xD;
      dose administrations of GIGA-2050 in patients hospitalized with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, first in human (FIH) study utilizing a 3+3 design to assess the safety and&#xD;
      pharmacology of single ascending doses (SAD) of GIGA-2050 in patients hospitalized with&#xD;
      confirmed COVID-19. Participants will receive a single intravenous (IV) infusion dose of&#xD;
      GIGA-2050 and followed for safety, pharmacology and efficacy assessments during&#xD;
      hospitalization, after discharge (if applicable), and through study discontinuation or end of&#xD;
      study visit (Day 56).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a Phase 1, first in human (FIH) study utilizing a 3+3 design to assess the safety and pharmacology of single ascending doses (SAD) of GIGA-2050 in patients hospitalized with confirmed COVID-19.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Day 1 up to Day 56</time_frame>
    <description>Frequency of TEAEs graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>Day 1 up to Day 3</time_frame>
    <description>Frequency of DLTs at each dose level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of vital signs, physical examination, and clinical laboratory assessments</measure>
    <time_frame>Day 1 up to Day 56</time_frame>
    <description>Numeric summaries of all observed findings and changes for vital signs, laboratory assessments, physical examinations, and ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of infusion-related reactions (IRR) and hypersensitivity reactions</measure>
    <time_frame>Day 1 through Day 2</time_frame>
    <description>Frequency of IRR and hypersensitivity reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacological evaluation of single doses of GIGA-2050</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>Serum titers of antibodies directed against SARS CoV-2 will be measured for the pharmacological profile of single doses of GIGA-2050</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>5 mg GIGA-2050 per kg BW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV infusion of 5 mg GIGA-2050 per kg BW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg GIGA-2050 per kg BW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV infusion of 15 mg GIGA-2050 per kg BW, or as determined by SRC review</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg GIGA-2050 per kg BW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV infusion of 50 mg GIGA-2050 per kg BW, or as determined by SRC review</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIGA-2050</intervention_name>
    <description>Recombinant Hyperimmune Polyclonal Antibody</description>
    <arm_group_label>15 mg GIGA-2050 per kg BW</arm_group_label>
    <arm_group_label>5 mg GIGA-2050 per kg BW</arm_group_label>
    <arm_group_label>50 mg GIGA-2050 per kg BW</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is ≥ 18 years of age.&#xD;
&#xD;
          -  Positive result of a SARS CoV-2 RNA diagnostic test result ≤48 hours before&#xD;
             enrollment, warranting hospital admission as per Investigator's judgement.&#xD;
&#xD;
          -  COVID-19 pneumonia findings on imaging (chest X-ray or CT Scan).&#xD;
&#xD;
          -  Requires oxygen supplementation with FIO2 approximately 30% or greater administered by&#xD;
             nasal cannula, mask, or NIV.&#xD;
&#xD;
          -  Participants can be on other medication on-label to treat COVID-19 respiratory disease&#xD;
             that the Investigator deems clinically relevant in combination with the study drug,&#xD;
             including corticosteroids. Passage of 24 hours after administration of the EUA drug&#xD;
             will be required prior to dosing GIGA-2050.&#xD;
&#xD;
          -  Men or non-lactating female participants who are surgically sterile or&#xD;
             post-menopausal, or a Woman of Childbearing Potential (WCBP) with a negative pregnancy&#xD;
             test at screening willing to use highly effective contraception methods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute respiratory failure requiring invasive mechanical ventilation or ECMO at&#xD;
             enrollment.&#xD;
&#xD;
          -  Systolic Blood Pressure (SBP) &lt;110 mmHg or heart rate &gt;120 bpm.&#xD;
&#xD;
          -  Pre-existing heart failure or unstable angina or myocardial infarction in the last&#xD;
             month prior to screening.&#xD;
&#xD;
          -  Pre-existing chronic respiratory condition(s).&#xD;
&#xD;
          -  Evidence of acute kidney injury, increase of serum creatinine of ≥1.5 x baseline, or&#xD;
             urine output of &lt;0.5mL/kg/hr sustained for at least 6 hours once volume repleted.&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) ≥2.5 x ULN, alanine aminotransferase (ALT) ≥2.5 x&#xD;
             ULN, and/or total bilirubin &gt;1.5 x ULN, or severe hepatic impairment.&#xD;
&#xD;
          -  Known systemic hypersensitivity to recombinant antibody therapies.&#xD;
&#xD;
          -  Female participant who is pregnant.&#xD;
&#xD;
          -  Participant is expected to transfer to a non-investigative facility from the&#xD;
             investigation site and cannot be monitored for compliance with protocol-required&#xD;
             safety monitoring procedures.&#xD;
&#xD;
          -  Participants who are currently participating or have participated in another clinical&#xD;
             trial within 30 days prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Keller</last_name>
    <phone>650 268 4255</phone>
    <email>gigagentrials@gigagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Liu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Keating SM, Mizrahi RA, Adams MS, Asensio MA, Benzie E, Carter KP, Chiang Y, Edgar RC, Gautam BK, Gras A, Leong J, Leong R, Lim YW, Manickam VA, Medina-Cucurella AV, Niedecken AR, Saini J, Simons JF, Spindler MJ, Stadtmiller K, Tinsley B, Wagner EK, Wayham N, Tracy L, Lundberg CV, Büscher D, Terencio JV, Roalfe L, Pearce E, Richardson H, Goldblatt D, Ramjag AT, Carrington CVF, Simmons G, Muench MO, Chamow SM, Monroe B, Olson C, Oguin TH, Lynch H, Jeanfreau R, Mosher RA, Walch MJ, Bartley CR, Ross CA, Meyer EH, Adler AS, Johnson DS. Generation of recombinant hyperimmune globulins from diverse B-cell repertoires. Nat Biotechnol. 2021 Aug;39(8):989-999. doi: 10.1038/s41587-021-00894-8. Epub 2021 Apr 15.</citation>
    <PMID>33859400</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No current plan to share IPD due to evaluation of potential DLTs.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

